A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Inclusion Criteria

• Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease or metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on CT/MRI for prostate cancer and have at least 1 lesion accessible for biopsy. For Part 2B participants with HCC, intermediate disease is allowed.
• Eastern Cooperative Oncology Group Performance Status of 0 or 1
• Must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to tumor type, if such a therapy exists
• Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permitted for some participants
• Willing and able to comply with all study procedures

Exclusion Criteria

• Primary central nervous system (CNS) malignancies, tumors with CNS metastases as the only site of disease or active brain metastases will be excluded
• Other active malignancy requiring concurrent intervention
• Prior organ allograft
• Active, known, or suspected autoimmune disease Other protocol-defined inclusion/exclusion criteria apply